Ibrutinib
规格
936563-96-1CAS 号
805-642-2EC 号
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-oneIUPAC 名称
C25H24N6O2化学式
440.5 g/mol分子量
Ibrutinib; 936563-96-1; PCI-32765; IMBRUVICA; PCI 32765; CRA-032765; PCI32765; ibrutinibum; Pc-32765; 1X70OSD4VX; PCI-32765-00; CHEBI:76612; DTXSID60893450; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; 1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one; 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; RefChem:57737; BTK Inhibitor PCI-32765; L01XE27; DTXCID601323465; 805-642-2; Ibrutinib (PCI-32765); (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; MFCD20261150; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; PCI-32765 (Ibrutinib); C25H24N6O2; 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1- yl)prop-2-en-1-one; Ibrutinib [USAN]; Ibrutinib [USAN:INN]; UNII-1X70OSD4VX; JNJ 02; Imbruvica (TN); 1-{(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1- yl}prop-2-en-1-one; Ibrutinib (Standard); CRA 032765; Ibrutinib, Free Base; IBRUTINIB [INN]; IBRUTINIB [JAN]; IBRUTINIB [MI]; Ibrutinib (JAN/USAN); Ibrutinib Intermediate 2; IBRUTINIB [VANDF]; IBRUTINIB [WHO-DD]; Imbruvica; PCI-32765; MLS006010041; SCHEMBL201859; Ibrutinib - Bio-X trade mark; GTPL6912; orb1307353; orb3141322; PCI-32765 (Ibrutinib)?; IBRUTINIB [ORANGE BOOK]; CHEMBL1873475; BDBM98652; HSDB 8260; EX-A066; XYFPWWZEPKGCCK-GOSISDBHSA-N; GLXC-90098; BDBM50357312; EBC-11432; HY-10997R; NSC800769; AKOS022185476; DB09053; EX-5960; FA34130; NSC-800769; NCGC00187912-01; NCGC00187912-02; NCGC00187912-03; NCGC00187912-12; NCGC00187912-16; NCGC00187912-17; NCGC00187912-18; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidyl]prop-2-en-1-one; AC-26942; BI164531; BP-43643; HY-10997; SMR004701213; NS00072153; SW218096-2; EN300-97039; D10223; F799864; A1-01649; Q5984881; BRD-K70301465-001-02-6; BRD-K70301465-001-05-9; Z1302446275; (R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-ylprop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 936563-96-1, Pci-32765, Imbruvica, Pci 32765, Ibrutinib (pci-32765), Pci-32765 (ibrutinib); Ibrutinib Micronized同义词
含有Ibrutinib的产品
임브루비카캡슐140밀리그램(이브루티닙)イムブルビカカプセル140mgIMBRUVICA 560 MG COMPRIMIDOS RECUBIERTOS CON PELICULAIMBRUVICA 420 MG COMPRIMIDOS RECUBIERTOS CON PELICULAIMBRUVICA 280 MG COMPRIMIDOS RECUBIERTOS CON PELICULAIMBRUVICA 140 MG COMPRIMIDOS RECUBIERTOS CON PELICULAIMBRUVICA 140 MG CAPSULAS DURASIMBRUVICA 140 MG CAPSULAS DURASIMBRUVICA 560 mg, comprimé pelliculéIMBRUVICA 420 mg, comprimé pelliculéIMBRUVICA 280 mg, comprimé pelliculéIMBRUVICA 140 mg, gélule
第 1/6 页
销售Ibrutinib的公司
AP
Aurobindo Pharma LimitedIndiaMP
Macleods Pharmaceuticals LimitedIndiaFK
Fresenius Kabi Oncology LimitedIndiaML
MSN LaboratoriesIndiaCI
CiplaIndia第 1/5 页